RU2014147741A - Модифицированные области антител и их применение - Google Patents
Модифицированные области антител и их применение Download PDFInfo
- Publication number
- RU2014147741A RU2014147741A RU2014147741A RU2014147741A RU2014147741A RU 2014147741 A RU2014147741 A RU 2014147741A RU 2014147741 A RU2014147741 A RU 2014147741A RU 2014147741 A RU2014147741 A RU 2014147741A RU 2014147741 A RU2014147741 A RU 2014147741A
- Authority
- RU
- Russia
- Prior art keywords
- region
- modified
- amino acid
- antibody
- positions
- Prior art date
Links
- 238000006467 substitution reaction Methods 0.000 claims abstract 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 22
- 125000000539 amino acid group Chemical group 0.000 claims abstract 21
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims abstract 20
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639729P | 2012-04-27 | 2012-04-27 | |
| US61/639,729 | 2012-04-27 | ||
| PCT/US2013/038538 WO2013163630A1 (en) | 2012-04-27 | 2013-04-26 | Modified antibody regions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014147741A true RU2014147741A (ru) | 2016-06-20 |
Family
ID=49483948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014147741A RU2014147741A (ru) | 2012-04-27 | 2013-04-26 | Модифицированные области антител и их применение |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150065690A1 (enExample) |
| EP (2) | EP3470433B1 (enExample) |
| JP (1) | JP6470170B2 (enExample) |
| KR (2) | KR20150008082A (enExample) |
| CN (1) | CN104428317B (enExample) |
| AU (3) | AU2013251309B2 (enExample) |
| BR (1) | BR112014026740B1 (enExample) |
| CA (1) | CA2871807C (enExample) |
| HK (1) | HK1207654A1 (enExample) |
| IN (1) | IN2014DN08721A (enExample) |
| MX (2) | MX382840B (enExample) |
| RU (1) | RU2014147741A (enExample) |
| WO (1) | WO2013163630A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2947605A1 (en) * | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| UA125378C2 (uk) * | 2016-03-14 | 2022-03-02 | Універшітетет І Осло | МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| AU2019371223B2 (en) * | 2018-10-31 | 2022-03-17 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| MX2021008144A (es) * | 2019-01-03 | 2021-10-13 | Invetx Inc | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP4014050A1 (en) | 2019-08-12 | 2022-06-22 | Voyager Therapeutics, Inc. | High-sensitivity immunoassay for the detection of frataxin in biofluids |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| EP4225787A4 (en) * | 2020-05-21 | 2024-10-23 | Zydus Lifesciences Limited | FC VARIANT AND PRODUCTION THEREOF |
| CN115803091A (zh) | 2020-05-22 | 2023-03-14 | 福迈康股份公司 | Ace2-fc融合蛋白及其用途 |
| EP4204091A2 (en) | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
| JP2024509543A (ja) | 2021-03-03 | 2024-03-04 | フォーマイコン アーゲー | ＡＣＥ２ Ｆｃ融合タンパク質の製剤 |
| WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
| WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
| EP4386084A1 (en) | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003286467B2 (en) * | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004041854A2 (en) | 2002-11-05 | 2004-05-21 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| EP1587540B1 (en) * | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| MX2007000404A (es) * | 2004-07-12 | 2008-03-04 | Macrogenics Inc | Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas. |
| BRPI0510674A (pt) * | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006105062A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| PL1919503T3 (pl) * | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| CA2625619A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
| ES2742268T3 (es) * | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| ES2675730T3 (es) * | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos |
| AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| TW201206473A (en) * | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8483058B2 (en) | 2010-08-17 | 2013-07-09 | Qualcomm Incorporated | Systems and methods for traffic policing |
| CN103648748B (zh) | 2011-07-15 | 2016-03-16 | 巴塞尔聚烯烃意大利有限责任公司 | 包含丙烯与1-己烯的无规共聚物的聚烯烃带 |
| IN2014CN03066A (enExample) * | 2011-09-30 | 2015-08-07 | Chugai Pharmaceutical Co Ltd | |
| EP2804952A4 (en) * | 2012-01-19 | 2015-09-09 | Therapeutic Proteins Int Llc | STABILIZATION OF ANTI-CD20 ANTIBODY RITUXIMAB |
-
2013
- 2013-04-26 WO PCT/US2013/038538 patent/WO2013163630A1/en not_active Ceased
- 2013-04-26 CA CA2871807A patent/CA2871807C/en active Active
- 2013-04-26 BR BR112014026740-5A patent/BR112014026740B1/pt active IP Right Grant
- 2013-04-26 HK HK15108290.3A patent/HK1207654A1/xx unknown
- 2013-04-26 KR KR1020147030719A patent/KR20150008082A/ko not_active Ceased
- 2013-04-26 AU AU2013251309A patent/AU2013251309B2/en active Active
- 2013-04-26 EP EP18209149.6A patent/EP3470433B1/en active Active
- 2013-04-26 CN CN201380022401.0A patent/CN104428317B/zh active Active
- 2013-04-26 RU RU2014147741A patent/RU2014147741A/ru unknown
- 2013-04-26 MX MX2018001914A patent/MX382840B/es unknown
- 2013-04-26 IN IN8721DEN2014 patent/IN2014DN08721A/en unknown
- 2013-04-26 JP JP2015509206A patent/JP6470170B2/ja active Active
- 2013-04-26 EP EP13781110.5A patent/EP2841458A4/en not_active Withdrawn
- 2013-04-26 MX MX2014012978A patent/MX360368B/es active IP Right Grant
- 2013-04-26 KR KR1020207009090A patent/KR20200037434A/ko not_active Ceased
- 2013-04-26 US US14/396,851 patent/US20150065690A1/en not_active Abandoned
-
2017
- 2017-09-08 AU AU2017225111A patent/AU2017225111B2/en active Active
-
2018
- 2018-03-02 US US15/910,588 patent/US10954288B2/en active Active
-
2019
- 2019-04-01 AU AU2019202229A patent/AU2019202229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2871807A1 (en) | 2013-10-31 |
| JP6470170B2 (ja) | 2019-02-13 |
| EP2841458A1 (en) | 2015-03-04 |
| AU2017225111A1 (en) | 2017-09-28 |
| CA2871807C (en) | 2022-10-04 |
| EP2841458A4 (en) | 2015-09-16 |
| US20180186863A1 (en) | 2018-07-05 |
| KR20200037434A (ko) | 2020-04-08 |
| US20150065690A1 (en) | 2015-03-05 |
| BR112014026740A2 (pt) | 2017-06-27 |
| IN2014DN08721A (enExample) | 2015-05-22 |
| BR112014026740A8 (pt) | 2021-06-15 |
| AU2017225111B2 (en) | 2019-01-03 |
| CN104428317A (zh) | 2015-03-18 |
| WO2013163630A1 (en) | 2013-10-31 |
| MX2014012978A (es) | 2015-02-05 |
| BR112014026740B1 (pt) | 2022-10-04 |
| AU2013251309A1 (en) | 2014-10-30 |
| EP3470433B1 (en) | 2025-12-03 |
| KR20150008082A (ko) | 2015-01-21 |
| MX382840B (es) | 2025-03-13 |
| JP2015515497A (ja) | 2015-05-28 |
| CN104428317B (zh) | 2018-08-28 |
| EP3470433A1 (en) | 2019-04-17 |
| HK1207654A1 (en) | 2016-02-05 |
| AU2019202229B2 (en) | 2021-02-11 |
| MX360368B (es) | 2018-10-29 |
| AU2019202229A1 (en) | 2019-04-18 |
| US10954288B2 (en) | 2021-03-23 |
| AU2013251309B2 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014147741A (ru) | Модифицированные области антител и их применение | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| EA201391789A1 (ru) | TNF-АЛЬФА АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, ОБЛАДАЮЩИЕ ПОВЫШЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
| ECSP15017314A (es) | Formulacion de anticuerpos | |
| BR112019021991A2 (pt) | Proteínas de ligação ao antígeno trem2 e seus usos | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| AU2011262758A8 (en) | Anti-tim-3 antibody | |
| UA117294C2 (uk) | Імунокон'югат | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| NZ705848A (en) | Anti-cd38 antibodies | |
| EA200702053A1 (ru) | Антитела против cd38 для лечения множественной миеломы | |
| EA201100228A1 (ru) | Структурные варианты антител для улучшения терапевтических характеристик | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| MY196756A (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| EA201491260A1 (ru) | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию | |
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon |